[Pharmacological studies on human urinary kallidinogenase (SK-827): cerebral protective effects].
We investigated the cerebral protective effects of human urinary kallidinogenase (SK-827) in rabbits. The following results were obtained: 1) At a dose of 5.0 x 10(-3) to 1.25 x 10(-2) PNA U/kg, SK-827 significantly inhibited the decrease of focal cerebral blood flow and the impairment of electrocorticogram (ECoG) activity in infarcted rabbits. 2) SK-827 at a dose of 2.5 x 10(-3) PNA U/kg inhibited the development of infarction area induced by internal carotid arterial injection of glass beads. 3) SK-827 at a dose of 2.5 x 10(-3) to 5.0 x 10(-3) PNA U/kg inhibited the decrease of cerebral cortical pO2 induced by 5% oxygen inhalation. 4) On subacute phase 7 days after the destruction of internal capsule, SK-827 at a dose of 1.25 x 10(-2) PNA U/kg improved the abnormality of spontaneous ECoG. These findings suggest that SK-827 minimizes the reduction of cerebral function induced by ischemia.
Nagano
H
H
Mie Research Laboratory, Sanwa Kagaku Kenkyusho Co., Ltd., Japan.
Suzuki
T
T
Nakamura
S
S
Tomoguri
T
T
Tanoue
T
T
Hayashi
M
M
Tsurumi
K
K
D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism; D002544:Cerebral Infarction / Q000503:physiopathology / Q000517:prevention & control; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000494:pharmacology* / Q000627:therapeutic use / Q000652:urine; D008297:Male; D010101:Oxygen Consumption; D011817:Rabbits
D007610:Kallikreins